The latest news, reliably.
Read, watch, or listen to the most recent announcements about Abzu.
Breaking news about Abzu and our achievements with our scientific AI.
Abzu® and Contera Pharma expand strategic partnership to add target identification to RNA therapeutic design platform.
The application designs RNA therapeutics through parallel hypotheses testing of drug targets and individual antisense oligonucleotide (ASO) drug properties.
The U.S. Patent and Trademark Office issues patent for the technology behind the pioneering QLattice® algorithm.
Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice algorithm.
Abzu in the news.
We’re just a bunch of nice nerds building something new and awesome. Some people have noticed.
Awards and recognition.
We are thrilled and honored to be recognized for our innovative and ethical technology and unique organization.
Watch Abzoids speak about their passions: scientific AI, entrepreneurship, and self-managing organizations.
Abzu’s Jonas Elsborg presents his research with NASA GeneLab: “Elucidating dermatological changes in spaceflight with explainable AI.”
The TOLAC project brings data-driven insights to expectant parents at important stages of pregnancy to reduce the risk inherent in vaginal or caesarian delivery.
See the Abzu Copenhagen office, and how we manage open-air collaboration, in 3 minutes.